208 related articles for article (PubMed ID: 36692427)
1. Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance.
Carney SV; Banerjee K; Mujeeb A; Zhu B; Haase S; Varela ML; Kadiyala P; Tronrud CE; Zhu Z; Mukherji D; Gorla P; Sun Y; Tagett R; Núñez FJ; Luo M; Luo W; Ljungman M; Liu Y; Xia Z; Schwendeman A; Qin T; Sartor MA; Costello JF; Cahill DP; Lowenstein PR; Castro MG
Clin Cancer Res; 2023 May; 29(9):1763-1782. PubMed ID: 36692427
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Reprogramming of Autophagy Drives Mutant IDH1 Glioma Progression and Response to Radiation.
Núñez FJ; Banerjee K; Mujeeb AA; Mauser A; Tronrud CE; Zhu Z; Taher A; Kadiyala P; Carney SV; Garcia-Fabiani MB; Comba A; Alghamri MS; McClellan BL; Faisal SM; Nwosu ZC; Hong HS; Qin T; Sartor MA; Ljungman M; Cheng SY; Appelman HD; Lowenstein PR; Lahann J; Lyssiotis CA; Castro MG
bioRxiv; 2024 Mar; ():. PubMed ID: 38559270
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.
Sachdev S; Dmello C; Sonabend AM
Clin Cancer Res; 2023 May; 29(9):1648-1650. PubMed ID: 36826993
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
5. Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.
Wang QX; Zhang PY; Li QQ; Tong ZJ; Wu JZ; Yu SP; Yu YC; Ding N; Leng XJ; Chang L; Xu JG; Sun SL; Yang Y; Li NG; Shi ZH
Eur J Med Chem; 2023 Sep; 257():115464. PubMed ID: 37235998
[TBL] [Abstract][Full Text] [Related]
6. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.
Dou C; Mo H; Chen T; Liu J; Zeng Y; Li S; Guo C; Zhang C
Pathol Res Pract; 2021 Mar; 219():153345. PubMed ID: 33517164
[TBL] [Abstract][Full Text] [Related]
7. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
[TBL] [Abstract][Full Text] [Related]
9. ZMYND8 Co-localizes with NuRD on Target Genes and Regulates Poly(ADP-Ribose)-Dependent Recruitment of GATAD2A/NuRD to Sites of DNA Damage.
Spruijt CG; Luijsterburg MS; Menafra R; Lindeboom RG; Jansen PW; Edupuganti RR; Baltissen MP; Wiegant WW; Voelker-Albert MC; Matarese F; Mensinga A; Poser I; Vos HR; Stunnenberg HG; van Attikum H; Vermeulen M
Cell Rep; 2016 Oct; 17(3):783-798. PubMed ID: 27732854
[TBL] [Abstract][Full Text] [Related]
10. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
[TBL] [Abstract][Full Text] [Related]
11. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
Fukunaga T; Fujita Y; Kishima H; Yamashita T
PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
[TBL] [Abstract][Full Text] [Related]
13. R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.
Sears TK; Woolard KD
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2275-2285. PubMed ID: 35467128
[TBL] [Abstract][Full Text] [Related]
14. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy.
Alghamri MS; McClellan BL; Avvari RP; Thalla R; Carney S; Hartlage CS; Haase S; Ventosa M; Taher A; Kamran N; Zhang L; Faisal SM; Núñez FJ; Garcia-Fabiani MB; Al-Holou WN; Orringer D; Hervey-Jumper S; Heth J; Patil PG; Eddy K; Merajver SD; Ulintz PJ; Welch J; Gao C; Liu J; Núñez G; Hambardzumyan D; Lowenstein PR; Castro MG
Sci Adv; 2021 Oct; 7(40):eabh3243. PubMed ID: 34586841
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Thomas D; Wu M; Nakauchi Y; Zheng M; Thompson-Peach CAL; Lim K; Landberg N; Köhnke T; Robinson N; Kaur S; Kutyna M; Stafford M; Hiwase D; Reinisch A; Peltz G; Majeti R
Cancer Discov; 2023 Feb; 13(2):496-515. PubMed ID: 36355448
[TBL] [Abstract][Full Text] [Related]
16. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
Sears TK; Horbinski CM; Woolard KD
J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
[TBL] [Abstract][Full Text] [Related]
17. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
18. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
[TBL] [Abstract][Full Text] [Related]
20. ZMYND8 suppresses MAPT213 LncRNA transcription to promote neuronal differentiation.
Adhikary S; Singh V; Choudhari R; Yang B; Adhikari S; Ramos EI; Chaudhuri S; Roy S; Gadad SS; Das C
Cell Death Dis; 2022 Sep; 13(9):766. PubMed ID: 36064715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
